Issued: 21 February 2025, London
UK
GSK
announces Dr Gavin Screaton to join the Board as Non-Executive
Director
Dr
Jesse Goodman to retire after 9 years of service
GSK plc (LSE/NYSE: GSK) has today
announced that Dr Gavin Screaton will join the Board of the Company
as a Non-Executive Director from 1 May 2025. Dr Screaton's
appointment follows a search to replace the skills and experience
of Dr Jesse Goodman who steps down from the Board after the
company's Annual General Meeting in May 2025, after nine years of
service.
Dr Screaton is currently Head of the
world-leading1
Medical Sciences Division at the University of
Oxford, and an expert in the field of immunology and infectious
diseases, two areas of science critical to GSK.
Dr Screaton is a Fellow of the
Academy of Medical Sciences, a Fellow of the Royal College of
Physicians, and a former Senior Investigator at the National
Institute for Health Research in the United Kingdom. He is also a
Non-Executive Director of Oxford University Hospitals NHS
Foundation Trust and a Trustee of the Jenner Vaccine Foundation. He
also co-founded RQ Bio, a biotech company focused on development of
preventative medicines to provide immunity and protection against
viral infectious diseases.
On appointment, Dr Screaton will
become a member of the GSK Board Science Committee and the
Corporate Responsibility Committee.
Sir
Jonathan Symonds, Chair of GSK said, "We are delighted to welcome Gavin to the Board of GSK. His
deep expertise in immunology and infectious diseases, which are
core areas of scientific research focus for GSK, together with his
considerable experience in public health, will bring valuable
perspective to the Board.
The appointment will also help to
replace the skillset and experience of Jesse Goodman who steps down
from the GSK Board after nine years of service. As a former FDA
Chief Scientist, the Board as a whole and the Science Committee in
particular, has benefitted hugely from Jesse's wealth of expertise
in infectious diseases, regulation and public health. He has made a
fantastic contribution to GSK and we wish Jesse all the very best
for the future."
_________________________
1The University of Oxford is ranked first in Times Higher
Education (THE) World University Rankings for Medicine, as of
January 2025. This is the 14th consecutive year that Oxford has led
the THE subject rankings in medicine.
Notes:
|
|
1. The appointment of Dr
Screaton was made by the Board on the recommendation of the
Nominations & Corporate Governance Committee. The Committee
conducted an extensive search and selection process for this
appointment, using an external search firm, which is a signatory of
the Voluntary Code of Conduct for Executive Search Firms. The
external search firm provided a comprehensive list of candidates
who were approached, evaluated and interviewed against an agreed
set of criteria aligned to the Board's target skills matrix. The
Board satisfied itself that Dr Screaton had the experience and time
available to carry out the role.
|
|
|
2. The Board has
determined that Dr Screaton is an independent Non-Executive
Director in accordance with the UK Corporate Governance
Code.
|
|
|
3. Dr Screaton will
receive the standard basic fee for a Non-Executive Director of
£122,258 per annum (including travel allowance). He will also
receive fees of £30,000 per annum as a scientific and medical
expert. Dr Screaton will be required to build towards a share
ownership requirement of GSK shares in accordance with the
Company's shareholder approved Non-Executive remuneration
policy.
|
|
|
4. "Scientific and
Medical Expert" - The Board designates Non-Executive Directors
whose expertise or backgrounds as renowned medical scientists,
researchers, or physicians mean that they can bring scientific or
industry expertise to the Board's deliberations.
|
|
|
5. Dr Screaton does not
have a service contract. He has a letter of appointment which may
be viewed by contacting the Company Secretary at the Company's
registered office.
|
|
|
6. There are no further
disclosures to be made in respect of Dr Screaton's appointment
under Listing Rule 6.4.8R
|
|
|
7. As of 1 May 2025, the
Board of GSK will comprise:
|
Sir Jonathan Symonds
|
Non-Executive Chair
|
|
Emma Walmsley
|
Chief Executive Officer
|
|
Julie Brown
|
Chief Financial Officer
|
|
Charles Bancroft
|
Senior Independent Non-Executive
Director
|
|
Elizabeth McKee Anderson
|
Independent Non-Executive
Director
|
|
Dr Hal Barron
|
Non-Executive Director
|
|
Dr Anne Beal
|
Independent Non-Executive
Director
|
|
Wendy Becker
|
Independent Non-Executive
Director
|
|
Dr Hal Dietz
|
Independent Non-Executive
Director
|
|
Dr Jesse Goodman
|
Independent Non-Executive
Director
|
|
Dr Jeannie Lee
|
Independent Non-Executive
Director
|
|
Dr Gavin Screaton
|
Independent Non-Executive
Director
|
|
Dr Vishal Sikka
|
Independent Non-Executive
Director
|
|
About GSK
GSK is a global biopharma company
with a purpose to unite science, technology, and talent to get
ahead of disease together. Find out more at gsk.com.
|
GSK
enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Annabel Brownrigg-Gleeson
|
+44 (0) 7901 101944
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described under Item 3.D "Risk factors" in GSK's
Annual Report on Form 20-F for 2023, and GSK's Q4 Results for
2024.
Registered in England & Wales:
No. 3888792
Registered Office:
79 New Oxford Street
London
WC1A 1DG
